Is There Still Potential in Keymed Biosciences After Shares Double in 2025?

Simply Wall St.09-14

Thinking about what to do with Keymed Biosciences stock? You are not alone. Investors have had to contend with some wild swings lately, and figuring out the right move feels more important than ever. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2567389168?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-09-14 23:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567389168","market":"us","top_or_hot":-1,"title":"Is There Still Potential in Keymed Biosciences After Shares Double in 2025?","media":"Simply Wall St.","content":"<div>\n<p>Thinking about what to do with Keymed Biosciences stock? You are not alone. Investors have had to contend with some wild swings lately, and figuring out the right move feels more important than ever. ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/is-there-still-potential-in-keymed-biosciences-after-shares\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is There Still Potential in Keymed Biosciences After Shares Double in 2025?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs There Still Potential in Keymed Biosciences After Shares Double in 2025?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-14 23:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/is-there-still-potential-in-keymed-biosciences-after-shares><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thinking about what to do with Keymed Biosciences stock? You are not alone. Investors have had to contend with some wild swings lately, and figuring out the right move feels more important than ever. ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/is-there-still-potential-in-keymed-biosciences-after-shares\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/is-there-still-potential-in-keymed-biosciences-after-shares","article_id":"2567389168","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/is-there-still-potential-in-keymed-biosciences-after-shares","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2567389168","pubTimestamp":1757864150,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Thinking about what to do with Keymed Biosciences stock? You are not alone. Investors have had to contend with some wild swings lately, and figuring out the right move feels more important than ever. After notching a remarkable 151.1% gain so far this year, Keymed’s shares more than doubled, leaving even longtime holders blinking at their account balances. Over the past year, the stock is up 91.1% and still riding close to multi-year highs. There was a 3.2% dip just last week and a slight...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","02162":"康诺亚-B","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","FCF":"第一联邦金融","BK1583":"高瓴概念"},"translate_title":"2025年股价翻倍后，Keymed Biosciences还有潜力吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":0.9,"DCF":1,"FCF":1},"content_text":"Thinking about what to do with Keymed Biosciences stock? You are not alone. Investors have had to contend with some wild swings lately, and figuring out the right move feels more important than ever. After notching a remarkable 151.1% gain so far this year, Keymed’s shares more than doubled, leaving even longtime holders blinking at their account balances. Over the past year, the stock is up 91.1% and still riding close to multi-year highs. There was a 3.2% dip just last week and a slight 2.8% gain over the last month. That is a big-picture win by almost any measure. Some of this action is tied to optimism about progress in the Chinese biotech sector, which has been fueled by supportive policy signals and increased global interest in up-and-coming healthcare companies. Investors seem to be re-calibrating the company’s risk profile as the market digests these shifts, pushing prices both higher and lower in short bursts. Plenty are now asking if Keymed is overextended or if there is still more room to run. That is where valuation comes in. According to traditional criteria, the company scores a 2 out of 6 when it comes to being undervalued, meaning it only passes two relevant checks. Is that enough to give you confidence? Let us break down these valuation methods and, more intriguingly, explore whether there is a smarter way to judge value that most investors miss. Keymed Biosciences scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Keymed Biosciences Discounted Cash Flow (DCF) Analysis The Discounted Cash Flow (DCF) model is a classic approach for valuing stocks by estimating all future cash flows that a business will generate and then discounting those projections back to today. This method is favored by serious investors because it assesses a company's intrinsic worth based on its underlying ability to generate cash, rather than relying on market sentiment or surface metrics. For Keymed Biosciences, analysts estimate the most recent twelve months’ Free Cash Flow (FCF) was approximately negative CN¥1.1 billion, which highlights significant current investment or losses typical in early-stage biotech firms. Looking ahead, forecasts suggest a sharp turnaround. By 2029, projections show FCF hitting CN¥789 million. Stretching further, Simply Wall St’s extended estimates point to over CN¥3 billion in annual FCF by 2035. These figures reflect expectations for significant growth as Keymed advances its drug pipeline and moves closer to commercial success. Applying the DCF model to all these numbers, the estimated intrinsic value per share comes to HK$169.76. Since this is about 55.3% higher than the current trading price, Keymed Biosciences appears to be substantially undervalued on this measure. Result: UNDERVALUED Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Keymed Biosciences. 2162 Discounted Cash Flow as at Sep 2025 Our Discounted Cash Flow (DCF) analysis suggests Keymed Biosciences is undervalued by 55.3%. Track this in your watchlist or portfolio, or discover more undervalued stocks. Approach 2: Keymed Biosciences Price vs Sales (P/S) Ratio The Price-to-Sales (P/S) ratio is a commonly used valuation tool for early-stage biotech companies like Keymed Biosciences, especially when earnings are negative or inconsistent. For businesses that are rapidly scaling but not yet profitable, revenue can offer a clearer gauge of market potential and operational momentum than earnings do at this stage. Growth expectations and risk both play key roles in what counts as a “normal” P/S ratio. Investors are often willing to pay a higher multiple for companies showing strong sales expansion or transformative pipelines. Greater risks and uncertainties around profitability can push the fair multiple down. Keymed’s current P/S ratio is 23.5x, notably higher than the biotech industry average of 19.9x and well above its peer group average of 14.0x. However, raw comparisons only reveal part of the picture. Simply Wall St’s proprietary “Fair Ratio” model sets what would be a justified P/S multiple at 21.6x for Keymed. This ratio reflects a nuanced mix of the company's growth potential, profit margin expectations, its market cap, industry context, and overall risk profile. Using the Fair Ratio is much more informative than relying solely on peer or industry averages. Instead of treating all companies as equal, it accounts for Keymed's unique characteristics and strategic position. In this case, Keymed’s actual multiple is only a touch above the Fair Ratio. That means the stock is priced about right based on expected growth, risks, and sector dynamics. Result: ABOUT RIGHT SEHK:2162 PS Ratio as at Sep 2025 PS ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Keymed Biosciences Narrative Earlier, we mentioned there is an even better way to understand valuation. Let us introduce you to Narratives. A Narrative is your story behind the numbers, combining your perspective on a company’s future (such as revenues, earnings, and margins) with your own estimate of fair value. Narratives help you connect what you believe about Keymed Biosciences, including its growth prospects, risks, and unique industry position, to a financial forecast and a calculated fair value. This approach is easy and accessible on Simply Wall St’s Community page, a resource used by millions of investors worldwide. Narratives allow you to quickly see whether your view of a company means it might be time to buy, hold, or sell, simply by comparing your Fair Value to the current market Price. In addition, these Narratives automatically update as new information, such as earnings releases or breaking biotech news, is released. This helps ensure your perspective stays current. For example, with Keymed Biosciences, one investor’s Narrative might point to a much higher fair value based on strong pipeline optimism, while another’s could set a lower fair value by taking a more cautious approach to future revenues. Narratives empower you to make decisions tailored to your unique outlook. Do you think there's more to the story for Keymed Biosciences? Create your own Narrative to let the Community know! SEHK:2162 Earnings & Revenue History as at Sep 2025  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Keymed Biosciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2567389168","isCrawlerRequest":true}